Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PPD’s Reputation Ranked Best of all CROs in Global Survey

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
No. 1 for innovation in improving site relationships and use of technology, data analytics.

Pharmaceutical Product Development, LLC (PPD) announced that clinical research sites globally ranked the company No. 1 for reputation among all contract research organizations (CROs) in CenterWatch’s 2013 Global Investigative Site Relationship Survey.

PPD also ranked second on investigative sites’ evaluation of their clinical trial relationships with CROs. Overall, PPD was ranked in the top three CROs on all 36 relationship attributes that the questionnaire asked of clinical research professionals at investigative sites globally.

Not only did four of every five survey respondents say PPD had an excellent or good reputation, PPD also ranked best in “being an innovator in finding ways to improve its relationships with sites and using technology to make processes more efficient, [using] data analytics to help target where sites might have a potential issue,” according to The CenterWatch Monthly, which published the survey results today. “PPD uses its analytics to improve productivity and quality across all project functions, not just monitoring.”

Clinical research professionals at 2,032 global sites completed the biennial survey, the largest CenterWatch has conducted to measure the quality of working relationships between CROs and sites conducting clinical research.

“These survey results are a real testament to the quality of the staff at PPD,” said Paul Colvin, PPD’s executive vice president, global clinical development. “We work to hire, train and retain the best team in the industry. We feel that trust, accountability, performance and results are the basis of PPD’s strong reputation within the industry and the foundation of our relationships with our biopharmaceutical clients and our investigative sites.

“Investigative sites are critical partners in clinical research,” Colvin said. “And strong site relationships are vital to our efforts to bend the cost and time curve of drug discovery and development to help our clients deliver life-changing medical therapies to the market faster, more cost effectively and with the highest possible quality.”

PPD’s best ranking for industry reputation follows its top overall CRO ranking in 2011, the last time CenterWatch conducted the global survey. PPD was rated highest in multiple categories that year, including staff professionalism, good protocol design, study initiation, being organized and prepared, and setting realistic project timelines. PPD also was rated one of Europe’s top CROs in the 2010 CenterWatch European Site Survey.

Since 1994, CenterWatch has been a global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals, ranging from top sponsors and CROs to research sites and niche providers, as well as an engaged population of patients interested in clinical research and volunteering.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PPD and HealthCore Collaborate
Goal is to establish new quality, cost and speed benchmarks for creating real-world clinical and economic evidence.
Friday, June 19, 2015
PPD Laboratories Opens Central Lab in Shanghai, China
Provides clients with broad range of standardized lab testing services and capabilities.
Friday, April 24, 2015
PPD and SNBL Complete Joint Venture
Joint venture to provide Japanese clinical development services and additional collaborations.
Friday, April 17, 2015
PPD Expands GMP Laboratory in Athlone, Ireland
Analytical testing facility adds cell-based lab capabilities.
Thursday, January 22, 2015
PPD Acquires RCT Logic’s Exclusive License to Patented Clinical Trial Design Technology
Expands PPD’s clinical development capabilities, particularly in neuroscience.
Thursday, September 04, 2014
PPD and Charité-Universitätsmedizin Berlin Announce Strategic Collaboration
Additional clinical trials to enhance health care delivery.
Saturday, March 01, 2014
PPD Acquires Acurian
Strengthens PPD’s comprehensive suite of feasibility, patient recruitment and retention services.
Thursday, August 29, 2013
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!